Revenue
0 Unit12
2020 Q4 · Unit12
Fundies. English
NextCure, Inc.
EDGAR40 filing records in this dataset, filed from 2019-04-12 to 2026-10-30. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating cash flow
-6.28 million Unit12
2020 Q4 · Unit12
Free cash flow
-7.26 million Unit12
2020 Q4 · Unit12
- Cash and cash equivalents
- 15.3 million Unit_Standard_USD_qWtHnWZfvk6Je6oAiT_t-A Source
Exact value
15260000 Unit_Standard_USD_qWtHnWZfvk6Je6oAiT_t-A
- Long-term debt including current maturities
- 0 Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg Source
Exact value
0 Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg
- Shares outstanding
- 4.07 million Unit_Standard_shares___r6RyoJJkenwqysN2pmrg Source
Exact value
4068951 Unit_Standard_shares___r6RyoJJkenwqysN2pmrg
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
22.4 million Unit12
2020-01-01 – 2020-12-31
Exact inputs and evidence
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-03-31 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-06-30 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-03-31 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-09-30 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-06-30 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-12-31 Source
- Revenue: 22378000 Unit12 · 2020-01-01 – 2020-09-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2020-12-31
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: Multiple units; comparison withheld· newest 2024-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2022-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 190,000Prior period
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 55.65 million
–
Current period
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 55.84 million
–
Exact inputs and evidence
-55844000 − -55654000 = -190000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ
-55654000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-55844000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 8.81 millionPrior period
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 40.81 million
–
Current period
−Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 49.61 million
–
Exact inputs and evidence
-49613000 − -40805000 = -8808000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ
-40805000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-49613000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 55.65 million Exact valueExact value: -55654000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 2024-01-01 – 2024-12-31: -55654000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 40.81 million Exact valueExact value: -40805000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 2024-01-01 – 2024-12-31: -40805000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 55.84 million Exact valueExact value: -55844000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 2025-01-01 – 2025-12-31: -55844000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 49.61 million Exact valueExact value: -49613000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ 2025-01-01 – 2025-12-31: -49613000 Unit_Standard_USD_u2HLnSi9nESgv27d-ShNLQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
40 filings · 3,174 latest values · 3,174 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001661059, 1661059, NXTC, edgar:1661059
Also known as NextCure, Inc.